INmune Bio Inc

INmune Bio, Inc. Is a clinical stage biotechnology company, which engages in developing new immunotherapies that reprograms the immune system to fight cancer and Alzheimer’s disease. Its products include pipeline, INKMUNE-Cancer, INB03-Cancer, XPRO1595-Alzheimer and TRD, and LIVNate. The company was founded by Mark Lowdell in September 2015 and is headquartered in Boca Raton, FL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

INmune Bio reports stable financials, eyes growth in diversified programs

INmune Bio's financials remain stable, with a strategic focus on advancing key programs and achieving upcoming milestones.
The company's strengths lie in efficient trial consolidation, diversification into solid tumors, and patient-centric treatment approaches.
Challenges include operational complexities, FDA holds, and the need for successful international site enrollments.
Opportunities for growth include new program launches, expansion into different therapeutic areas, and exploring combination therapies.

INmune Bio advances Alzheimer's and cancer treatments amidst financial strength

INmune Bio's Q1 2023 performance reflects a focus on advancing treatments for Alzheimer's, cancer, and other diseases, supported by a strong financial position.
While facing challenges such as FDA clinical hold and resource allocation, the company's commitment to innovation and diversification presents growth opportunities.
With upcoming milestones and a promising pipeline, INmune Bio is poised to make significant strides in addressing critical medical needs and expanding its therapeutic reach.

INmune Bio reports Q2 loss, progresses in Alzheimer's and solid tumors

INmune Bio's Q2 2023 earnings call highlighted progress in Alzheimer's and solid tumor treatments, with positive effects observed on gray matter microstructure.
The company's financials showed a net loss but with sufficient cash reserves for operations, while upcoming milestones signal growth potential.
Challenges include managing losses, regulatory progress, and market strategies, but opportunities lie in therapeutic advancements and diversification.

INmune Bio advances Alzheimer's and cancer trials amidst financial challenges

INmune Bio made progress in patient enrollment for Alzheimer's and prostate cancer trials, with a focus on regulatory milestones. Financially, the company reported a net loss but maintains a healthy cash position. Challenges include regulatory hurdles and competition, while opportunities exist in upcoming milestones and market expansion.

INmune Bio advances Alzheimer's and prostate cancer trials amid financial challenges

INmune Bio's Q4 2023 Earnings Call highlighted progress in Alzheimer's and prostate cancer trials, with positive regulatory developments. Financially, the company reported a net loss but maintains a healthy cash position. Analyst questions focused on trial specifics and market comparisons.

INmune Bio Inc advances Alzheimer's trials and secures funding for growth

INmune Bio Inc's Q2 2024 showcased progress in Alzheimer's trials, successful fundraising, and strategic milestones ahead
The company's leadership, financial stability, and upcoming trials position it well for growth and market recognition
While facing competitive challenges and operational complexities, INmune Bio Inc remains focused on innovation and market expansion

INmune Bio excels in clinical trials, secures funding for growth

INmune Bio's Q3 2024 earnings call highlighted strong clinical progress, financial growth, and a focus on data-driven decision-making for future success.
The company's emphasis on quality standards, innovative drug delivery, and promising trial results positions them well for upcoming milestones and market impact.
While facing inquiries and challenges, INmune Bio remains confident in its programs, signaling a resilient approach to addressing industry complexities and driving growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The FDA places clinical hold on INmune Bio's (INMB) IND application to begin a phase II study on the investigational TNF inhibitor, XPro1595, for Alzheimer's disease.

INmune Bio (INMB) Down on Clinical Hold for Alzheimer's Study

INmune Bio's XPro is probably the most-promising drug candidate in the history of neurodegenerative diseases. INMB's share price just dropped at an all-time low due to a US-related clinical hold for XPro.

INmune Bio: Possibly The Once In A Lifetime Dip

Shares of INmune Bio Inc. INMB, -1.09% plummeted 31.4% toward a 22-month low in premarket trading Tuesday, after the Florida-based biotechnology company said it received an email from U.S. Food and Drug Administration, saying that it placed the Investigational New Drug (IND) application to initiate its Phase 2 trial of its XPro Alzheimer's treatment on clinical hold. Also in the email, the FDA requested additional information around Chemistry Manufacturing and Controls (CMC) regarding the company's newly manufactured XPro1595.

INmune Bio stock plunges after clinical hold of IND of Alzheimer's treatment prompts analyst downgrade

BOCA RATON, FL., May 23, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc.  (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient's innate immune system to fight disease, today announced that on May 20, 2022, the Company was informed via e-mail communication from the U.S. Food and Drug Administration (FDA) requesting additional information around Chemistry Manufacturing and Controls (CMC) of the newly manufactured XPro1595 (XPro™).  As part of the communication, the Agency placed the Company's Investigational New Drug (IND) application to initiate its Phase 2 clinical trial of XPro™ in patients with Alzheimer's Disease (AD) in the U.S. on clinical hold.  The FDA indicated they will provide an official clinical hold letter to INmune in approximately 30 days.  INmune plans to provide additional updates pending discussion with the FDA.  The Phase 2 trial of XPro™ remains open in Australia and continues to enroll patients.

INmune Bio, Inc. to Provide Additional Manufacturing Information to FDA as Part of IND Application for XPro1595™ in Alzheimer's Disease

Boca Raton, FL, May 18, 2022 (GLOBE NEWSWIRE) -- INmune Bio (NASDAQ: INMB), a clinical stage immunology company focused on developing treatments that harness the patient's immune system to fight disease, announced today that David Moss, Chief Financial Officer will present a corporate overview at the H.C. Wainwright Global Hybrid Investment Conference. The conference is being held on May 23 – 26, 2022 at the Fontainebleau Hotel in Miami Beach, FL.

INmune Bio, Inc. to Present at the H.C. Wainwright Global Hybrid Investment Conference on May 24th

XPro™ Promotes Remyelination in a Cuprizone Model of Multiple Sclerosis(MS) by Improving Macrophage Phagocytosis (clearing) of Myelin Debris

INmune Bio, Inc. Presents Data Demonstrating XPro™ Promotes Remyelination in Gray Matter at 3rd European Conference on Neuroinflammation

INmune Bio, Inc. (NASDAQ:INMB ) Q1 2022 Earnings Conference Call May 5, 2022 4:30 PM ET Company Participants David Moss – Co-Founder and Chief Financial Officer RJ Tesi – Chairman and Chief Executive Officer CJ Barnum – Head of Neuroscience Conference Call Participants William Wood – B. Riley Securities Matthew Cross – Alliance Global Partners Sung Hong – BTIG Daniel Carlson – TW Research Group Operator Greetings, and welcome to the INmune Bio First Quarter 2022 Earnings Call.

INmune Bio's (INMB) CEO RJ Tesi on Q1 2022 Results - Earnings Call Transcript

Company Dosed First Phase 2 Mild Alzheimer's Disease Patient with Xpro1595; Presented Data from Ongoing INKmune™ Studies Suggesting Increased NK Cell Treatment Effective Against Solid Malignancies

INmune Bio, Inc. Announces First Quarter 2022 Results and Provides Business Update

Management to host conference call and webcast at 4:30 pm ET on that day Management to host conference call and webcast at 4:30 pm ET on that day

INmune Bio, Inc. to Report First Quarter 2022 Financial Results and Provide a Corporate Update on Thursday, May 5

Boca Raton, FL, April 25, 2022 (GLOBE NEWSWIRE) -- INmune Bio (NASDAQ: INMB), a clinical stage immunology company focused on developing treatments that harness the patient's immune system to fight disease, announced today that management will participate at the B. Riley Neuro & Ophthalmology Conference which is being held virtually on April 28, 2022.

INmune Bio, Inc. to Participate at the B. Riley Neuro & Ophthalmology Conference

INmune (INMB) doses the first patient in a phase II study with its investigational TNF inhibitor to treat Alzheimer's disease. Stock rises more than 12% post this announcement.

INmune (INMB) Begins Dosing in Mid-Stage Study With AD Candidate

INmune Bio Plans to Enroll 201 Patients in a 6-Month Study to Evaluate Cognitive Function in Patients with Mild Alzheimer's Disease INmune Bio Plans to Enroll 201 Patients in a 6-Month Study to Evaluate Cognitive Function in Patients with Mild Alzheimer's Disease

INmune Bio Announces First Patient Dosed in Phase 2 XPro1595 Trial for Treatment of Neuroinflammation as a Cause of Alzheimer's disease

Data from animal models of trastuzumab-resistant MUC4 HER2+ breast cancer show that treatment with INB03 decreases MUC4 expression, reverses resistance to trastuzumab and tyrosine kinase inhibitors, and promotes an immunologically active tumor micro-environment

INmune Bio, Inc. to Present Preclinical Data on INB03 at the American Association for Cancer Research (AACR) Annual Meeting 2022

INKmune therapy, NK cell therapy, was shown to activate NK cells that killed off >70% of NK resistant tumor cells in an in vitro assay in an MDS patient.

INmune Bio: Speculative Biotech With 2 Solid Potential Approaches To Treating AD And Solid Tumors

INKmune™, unlike IL15 and other NK-activating cytokines, upregulates all mitochondrial survival proteins and more than 40 nutrient receptors on the NK cell to increase survival

INmune Bio, Inc. Highlights INKmune™ Data Featured in NK Cells in Solid Tumors Workshop at Innate Killer Summit

The Company also Plans on Sharing INKmune™ Patient Case Studies The Company also Plans on Sharing INKmune™ Patient Case Studies

INmune Bio, Inc. Announces Company's CSO Dr. Mark Lowdell to Co-Host the “NK Cells in Solid Tumors” Workshop at Innate Killer Summit

International Conference on Alzheimer's and Parkinson's Diseases Provides New Insights into the Role of Neuroinflammation in AD and the Promise of Xpro™ for Treatment International Conference on Alzheimer's and Parkinson's Diseases Provides New Insights into the Role of Neuroinflammation in AD and the Promise of Xpro™ for Treatment

INmune Bio, Inc. Spotlights Key Findings in Presentations at AD/PD™ 2022

Conference Provides First Exposure of EU and UK AD Experts to INmune Bio's Approach of Targeting Neuroinflammation and Glial Activation with XPro™ for Treatment of Alzheimer's Disease

INmune Bio, Inc. Announces Nine Data Presentations at AD/PD™ 2022 - International Conference on Alzheimer's and Parkinson's Diseases

Boca Raton, FL, March 14, 2022 (GLOBE NEWSWIRE) -- INmune Bio (NASDAQ: INMB), a clinical stage immunology company focused on developing treatments that harness the patient's immune system to fight disease, announced today that RJ Tesi, MD., President and CEO has been invited to participate in the 32nd Annual Oppenheimer Healthcare Conference and the 2022 Maxim Group Virtual Growth Conference.

INmune Bio, Inc. to Participate in the 32nd Annual Oppenheimer Healthcare Conference and the 2022 Maxim Group Virtual Growth Conference

INmune Bio, Inc. (INMB) CEO Raymond J. Tesi on Q4 2021 Results - Earnings Call Transcript

Opens Phase 2 mild Alzheimer's trial and reports positive patient data from ongoing INKmuneTM trial in patient with high-risk myelodysplastic syndrome Opens Phase 2 mild Alzheimer's trial and reports positive patient data from ongoing INKmuneTM trial in patient with high-risk myelodysplastic syndrome

INmune Bio, Inc. Announces Fourth Quarter and Full Year 2021 Results and Provides Business Update

Management to host conference call and webcast at 4:30 pm ET on that day

INmune Bio, Inc. to Report Fourth Quarter 2021 Financial Results and Provide a Corporate Update on Thursday, March 3

BOCA RATON, Florida., Feb. 08, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc.  (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient's innate immune system to fight disease, today announced that Raymond J. Tesi, MD, President and CEO, will present at the BIO CEO & Investor Conference being held February 14 – 17 at the Marriott Marquis in New York City.

INmune Bio, Inc. to Present at the BIO CEO & Investor Conference

Boca Raton, Florida, Jan. 25, 2022 (GLOBE NEWSWIRE) -- INmune  Bio, Inc.  (NASDAQ: INMB) (“INMB” or “the Company”), a clinical-stage immunology company focused on developing treatments that harness the patient's innate immune system to fight disease, today announced that the company has entered into a pre-clinical research collaboration with Chinese University of Hong Kong (CUHK) to evaluate INKmune™ -- the company's pseudokine NK cell priming platform -- in nasopharyngeal cancer (NPC), a type of head and neck cancer.

INmune Bio, Inc. Announces Research Collaboration with Chinese University of Hong Kong to Evaluate INKmune in Nasopharyngeal Cancer

Cassava Sciences Inc

Both Cassava Sciences and INmune Bio have brought impressive results on neuroinflammation and neurodegeneration. I expect INmune Bio's XPro to yield impressive results in its phase 2 trials like Cassava Sciences' simufilam did.

News for INmune Bio Inc Stock (INMB)